The ADDF offers funding to researchers in both nonprofit and for-profit organizations for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through the following RFPs. For returning grantees, we accept proposals for follow-on funding and renewals.

We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is less than four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.

CORE REQUESTS FOR PROPOSALS


Preclinical Drug Discovery RFP

Purpose:

Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer's disease, related dementias and cognitive aging.

Next Deadlines: (4/year)

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

 
 

Program to Accelerate Clinical Trials (PACT) RFP

Purpose:

Seeks to fund biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials.

Next Deadlines: (4/year)

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

 
 

Biomarkers Development RFP

Purpose:

Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

Next Deadlines: (4/year)

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

 
 

Prevention Beyond the Pipeline RFP

Purpose:

Seeks to support prevention drug discovery not covered by most research funders or our current RFPs.

Next Deadlines: (4/year)

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

 

 

OTHER REQUESTS FOR PROPOSALS


ADDF-Harrington Scholar Program RFP

Purpose:

Awards recipients with research funding and committed project support with the goal of developing new therapies through a partnership with the Harrington Discovery Institute.

Deadlines:

Letter of Intent: March 17, 2017
Invited Full Proposal: July 14, 2017

 
 

ADDF/NIH RFP

Purpose:

The RFP supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.

Next Deadline:

Proposals accepted on a rolling basis

 
 

Clinical Trials for Frontotemporal Degeneration RFP

Purpose:

Supports clinical trials of novel or repurposed drugs for FTD and related disorders (bvFTD, PPA, PSP, CBD, FTD/ALS) through a partnership with The Association for Frontotemporal Degeneration.

Next Deadline:

Passed

 
 

Conference Funding

ADDF supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information email us or apply online.

 


Considerations

Support is provided for personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials. Support is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel.

 

Review Process

  • If your LOI is approved by ADDF scientific staff, you will receive an email with a link to submit your Invited Full Proposal. Before you submit, review the Application Instructions for each RFP. Applicants from biotechnology companies should also review the Program-Related Investments (PRIs) Policy Statement (PDF).
  • Invited proposals are reviewed externally by members of our Scientific Review Board, which includes scientists from academia and industry with drug discovery expertise. Biotechnology proposals are also reviewed by a member of our Business Review Board.
  • All review Board members sign annual confidential disclosure agreements and must recuse themselves from reviewing any proposals with which they have a conflict of interest.
  • On average, applicants are notified of decisions three months after full proposal submission.
  • Note: Applicants unable to submit the full proposal by the deadline may submit their proposal during the next cycle without submitting a new LOI, unless the proposed work has changed. After two missed deadlines, applicants must submit a new LOI.

All ADDF Governors, officers, and advisory committee members who participate in the selection of recipients for research grant funding are required to annually complete conflict of interest questionnaires to avoid conflicts of interest and maintain high ethical standards.

 

Restrictions

  • Please note that applicants may only submit one proposal per cycle, but a single institution may have multiple applicants apply for funding for different projects.
  • Applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.

 


Stay Updated on Upcoming Deadlines and RFP Announcements

Sign up to receive news by email.

Print